CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.8200
-0.0600 (-3.19%)
At close: 2:45PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.8800
Open1.9000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.8100 - 2.0900
52 Week Range1.2500 - 5.8300
Volume22,583
Avg. Volume38,973
Market Cap69.22M
Beta (5Y Monthly)3.18
PE Ratio (TTM)N/A
EPS (TTM)-0.6960
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    CURE Pharmaceutical Expands to Mexico in Collaboration with Factoria Bogar Subsidiary

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery platform, CUREform™ for its drug formulation, as well as become its distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep and CBD combination products.

  • GlobeNewswire

    CURE Pharmaceutical Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. “Adding CBG to our SCFE patent portfolio aligns with the latest research and early clinical evidence supporting its therapeutic benefit,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using its proprietary drug delivery systems, including its lead drug product, CUREfilm Blue™, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED) in China. “Securing this key patent supports our global commercialization strategy for CUREfilm Blue as well as follow-on drugs delivered using thin film,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers. “This license agreement gives operational freedom to a leader in the supercritical fluid extraction industry who is committed to pharma-grade standards continuing our powered by Cure licensing strategy,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products. ReLeaf Europe products will be the first to use the CUREinside™ quality mark to bolster consumer confidence.

  • GlobeNewswire

    CURE Pharmaceutical to Present at the 12th Annual LD Micro Main Event Investor Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 12th Annual LD Micro Main Event on Wednesday, December 11 at 9:45 AM PST/ 12:45 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles. CEO Rob Davidson will be presenting and meeting with investors. “CURE is seeing an acceleration in contract manufacturing of wellness products using our advanced oral delivery technologies,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors. “John’s unparalleled depth and breadth of expertise makes him an invaluable asset to our growth strategy,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

    OXNARD, Calif., Nov. 14, 2019 -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000.

  • GlobeNewswire

    CURE Pharmaceutical  Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds CUREpods™ chewables and emulsions to meet increased demand for alternative dosage forms that can improve solubility and absorption. “Building on the market demand for CUREfilm for nutraceutical and pharmaceutical applications, we are expanding our oral formulation platform to redefine how medications are delivered and experienced,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and development.

  • GlobeNewswire

    CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms 

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, CUREfilm®. “The agreement with Fytiko Farms is a crucial step in CURE’s effort to secure our CBD supply chain and also includes preferred pricing for CURE,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Expands Board with Two Women Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both business and law for startup and technology companies. “Dr. Chung and Mrs. Goldin bring a wealth of expertise and insights to CURE as we hit a solid growth stride,” says Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. “The challenge with oral soluble film technology is creating a fast-dissolving and pleasant-tasting film that packs a high dose of medication – 50mg or higher per unit,” said Rob Davidson, CEO of CURE Pharmaceutical. The new patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes.

  • GlobeNewswire

    CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With an increased consumer demand for natural wellness products, one of our areas of focus is to improve the delivery plant components and extracts in novel ways,” said Rob Davidson, CEO at CURE Pharmaceutical. The patent expands on CURE’s proprietary drug delivery system, CUREfilm™ to include bi-phasic release of natural active ingredients with the potential for increasing the overall drug load while retaining a rapid dissolution profile.

  • GlobeNewswire

    CURE Pharmaceutical and Canopy Growth to Produce CBD Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.